Identification and Quantification of MIDD0301 metabolites
M.S. Rashid Roni, Nicolas M. Zahn, Brandon N. Mikulsky, Daniel A. Webb, Md Yeunus Mian, Daniel E. Knutson, Margaret L. Guthrie, James M. Cook, Douglas C. Stafford, Leggy A. Arnold*
Current Drug Metabolism 2021

Nebulized MIDD0301 Reduces Airway Hyperresponsiveness in Moderate and Severe Murine Asthma Models
Nicolas M. Zahn, Brandon N. Mikulsky, M. S. Rashid Roni, Gene T. Yocum, Md Yeunus Mian, Daniel E. Knutson, James M. Cook, Charles W. Emala, Douglas C. Stafford, and Leggy A. Arnold*
ACS Pharmacology & Translational Science 2020, 3(6), 1382-1390

Design, synthesis and characterization of novel gamma aminobutyric acid type A receptor ligands
Kamal P. Pandey, Md Zubair Ahmed Khan, Lalit K. Golani, Prithu Mondal, Md Yeunus Mian, Farjana Rashid, V. V. N. Phani Babu Tiruveedhula, Daniel E. Knutson, Nicolas M. Zahn, Leggy A. Arnold, Jeffrey M. Witkin and James M. Cook*
Arkivoc 2020, (Pt 7), 242-256.

A Structure-Activity Relationship Comparison of Imidazodiazepines Binding at Kappa, Mu, and Delta Opioid Receptors and the GABAA Receptor
Guanguan Li, Amanda N. Nieman, Md Yeunus Mian, Nicolas M. Zahn, Brandon N. Mikulsky, Michael M. Poe, Kashi R. Methuku, Yongfeng Liu, James M. Cook, Douglas C. Stafford, and Leggy A. Arnold*
Molecules 2020, 25(17), E3864.

Improved scale-up synthesis and purification of clinical asthma candidate MIDD0301
Daniel E. Knutson, M.S. Rashid Roni, Md Yeunus Mian, James M. Cook, Douglas C. Stafford, and Leggy A. Arnold*
Organic Process Research & Development 2020, 24(8), 1467-1476.

Targeting Nitric Oxide Production in Microglia with Novel Imidazodiazepines for Nonsedative Pain Treatment
Amanda N. Nieman, Guanguan Li, Nicolas M. Zahn, Md Yeunus Mian, Brandon N. Mikulsky, Dylan A. Hoffman, Taylor M. Wilcox, Alexander S. Kehoe, Ian W. Luecke, Michael M. Poe, David Alvarez-Carbonell, James M. Cook, Douglas C. Stafford, and Leggy A. Arnold*
ACS Chemical Neuroscience 2020, 11(13), 2019-2030.

The effects of pH on the structure and bioavailability of imidazobenzodiazepine-3-carboxylate MIDD0301
M.S. Rashid Roni, Guanguan Li, Brandon N. Mikulsky, Daniel E. Knutson, Md Yeunus Mian, Nicolas M. Zahn, James M. Cook, Douglas C. Stafford and Leggy A. Arnold*
Molecular Pharmaceutics 2020, 17(4), 1182-1192.

Novel Benzodiazepine-Like Ligands with Various Anxiolytic, Antidepressant, or Pro-Cognitive Profiles
Thomas D. Prevot, Guanguan Li, Aleksandra Vidojevic, Keith A. Misquitta, Corey Fee, Anja Santrac, Daniel E. Knutson, Michael R. Stephen, Revathi Kodali, Nicolas M. Zahn, Leggy A. Arnold, Petra Scholze, Janet L. Fisher, Bojan D. Marković, Mounira Banasr, James M. Cook, Miroslav Savic and Etienne Sibille*
Molecular Neuropsychiatry 2019, 5, 84-97.

MIDD0301 ‒ A first-in-class anti-inflammatory asthma drug targets GABAA receptors without causing systemic immune suppression
Nicolas M. Zahn, Alec T. Huber, Brandon Nicholas Mikulsky, Mae Elizabeth Stepanski, Alexander Scott Kehoe, Guanguan Li, Melissa Schussman, M. S. Rashid Roni, Revathi Kodali, James M. Cook, Douglas C. Stafford, Douglas A. Steeber and Leggy A. Arnold*
Basic & Clinical Pharmacology & Toxicology 2019, 125, 75-84.

Novel GABAA Receptor Ligand MIDD0301 with Limited Blood-Brain Barrier Penetration Relaxes Airway Smooth Muscle Ex Vivo and In Vivo
Gene T Yocum, Jose F Perez-Zoghbi, Jennifer Danielsson, Aisha S Kuforiji, Yi Zhang, Guanguan Li, MS Rashid Roni, Revathi Kodali, Douglas C Stafford, Leggy A Arnold, James M Cook, Charles W Emala Sr*
American Journal of Physiology-Lung Cellular and Molecular Physiology 2018, 61, 9132-9145

A novel orally available asthma drug candidate that reduces smooth muscle constriction and inflammation by targeting GABA(A) receptors in the lung
Gloria S. Forkuo, Amanda N. Nieman, Revathi Kodali, Nicolas M. Zahn, Guanguan Li, M. S. Rashid Roni, Michael Rajesh Stephen, Ted W. Harris, Rajwana Jahan, Margaret L. Guthrie, Olivia B. Yu, Janet L. Fisher, Gene T. Yocum, Charles W. Emala, Douglas A. Steeber, Douglas C. Stafford, James M. Cook, and Leggy A. Arnold*
Molecular Pharmaceutics 2018, 15, 1766-1777.

Synthesis of chiral GABA(A) receptor subtype selective ligands as potential agents to treat schizophrenia as well as depression
Guanguan Li, Michael R. Stephen, Revathi Kodali, Nicolas M. Zahn, Michael M. Poe, V.V.N. Phani Babu Tiruveedhula, Alec T. Huber, Melissa K. Schussman, Krista Qualmann, Cristina M. Panhans, Nicholas J. Raddatz, David A. Baker, Thomas D. Prevot, Mounira Banasr, Etienne Sibille, Leggy A. Arnold, and James M. Cook*
Arkivoc 2018, 4, 158-183.

Design and Synthesis of Novel Deuterated Ligands Functionally Selective for the γ-Aminobutyric Acid Type A Receptor (GABA(A)R) α6 Subtype with Improved Metabolic Stability and Enhanced Bioavailability
Daniel E. Knutson, Revathi Kodali, Michael R. Stephen, Ranjit S. Verma, Christopher Witzigmann, Matheus A. Meirelles, Nicolas M. Zahn, Alec T. Huber, Leggy A. Arnold, Branka Divović, Vladimir Dobričić, Miroslav M. Savić, Marko D. Mihovilovic, Laurin Wimmer, Marco Treven, Lih-Chu Chiou, Margot Ernst, Werner Sieghart, and James M. Cook*
Journal of Medicinal Chemistry 2018, 61, 2422-2442.

Identification of a novel, fast acting GABAergic anti-depressant
Katherine M. J. McMurray, Marcia J. Ramaker, Preetpal S. Sidhu, Pavel Elkin, James M. Cook, Viresh Rawal, Leggy A. Arnold, Stephanie C. Dulawa, Abraham A. Palmer*
Molecular Psychiatry 2018, 23, 384-391.

Alleviation of Multiple Asthmatic Pathologic Features with Orally Available and Subtype Selective GABA(A) Receptor Modulators
Gloria S. Forkuo, Amanda N. Nieman, Nina Y. Yuan, Revathi Kodali, Olivia B. Yu, Nicolas M. Zahn, Rajwana Jahan, Guanguan Li, Michael Rajesh Stephen, Margaret L. Guthrie, Michael M. Poe, Benjamin D. Hartzler, Ted W. Harris, Gene T. Yocum, Charles W. Emala, Douglas A. Steeber, Douglas C. Stafford, James M. Cook and Leggy A. Arnold*
Molecular Pharmaceutics 2017, 14, 2088-2098.

Further evaluation of the potential anxiolytic activity of imidazo[1,5-a][1,4]diazepin agents selective for α2/3-containing GABAA receptors
Jeffrey M. Witkin,* Rok Cerne, M. Wakulchik, J. S., S.D. Gleason, Timothy M. Jones, Guanguan Li, Leggy A. Arnold, Jun-Xu Li, Jeffrey M. Schkeryantz, Kashi R. Methuku, James M. Cook, Michael M. Poe
Pharmacology, Biochemistry and Behavior 2017, 157, 35-40.

Pharmacological and antihyperalgesic properties of the novel α2/3 preferring GABAA receptor ligand MP-III-024
Bradford D. Fischer*, Raymond J. Schlitt, Bryan Z Hamade, Sabah Rehman, Margot Ernst, Michael M. Poe, Guanguan Li, Revathi Kodali, Leggy A. Arnold, James M. Cook
Brain Research Bulletin 2017, 131, 62-69.

Optimization of substituted imidazobenzodiazepines as novel asthma treatments
Rajwana Jahana, Michael R. Stephen, Gloria S. Forkuo, Revathi Kodali, Margaret L. Guthrie, Amanda N. Nieman, Nina Y. Yuan, Nicolas M. Zahn, Michael M. Poe, Guanguan Li, Olivia B. Yu, Gene T. Yocum, Charles W. Emala, Douglas C. Stafford, James M. Cook, Leggy A. Arnold*
Journal of European Medicinal Chemistry 2017, 126, 550-560.

Characterization of GABA(A) receptor ligands with automated patch-clamp using human neurons derived from pluripotent stem cells
Nina Y. Yuan, Michael M. Poe, Christopher Witzigmann, James M. Cook, Douglas Stafford, Leggy A. Arnold*
Journal of Pharmacological and Toxicological Methods 2016, 82, 109-114.

Development of GABA(A) Receptor Subtype-Selective Imidazobenzodiazepines as Novel Asthma treatments
Gloria S. Forkuo, Margaret L. Guthrie, Nina Y. Yuan, Amanda N. Nieman, Revathi Kodali, Rajwana Jahan, Michael R. Stephen, Gene T. Yocum, Marco Treven, Michael M. Poe, Guanguan Li, Olivia B.Yu, Benjamin D. Hartzler, Nicolas M. Zahn , Margot Ernst, Charles W. Emala, Douglas C. Stafford, James M. Cook, and Leggy A. Arnold*
Molecular Pharmaceutics 2016, 13(6), 2026-38

A Review of the Updated Pharmacophore for the Alpha 5 GABA(A) Benzodiazepine Receptor Model
Terry Clayton, Michael M. Poe, Sundari Rallapalli, Poonam Biawat, Miroslav M. Savić, James K. Rowlett, George Gallos, Charles W. Emala, Catherine C. Kaczorowski, Douglas C. Stafford, Leggy A. Arnold and James M. Cook*
International Journal of Medicinal Chemistry 2015, ID 430248.

Glo1 inhibitors for neuropsychiatric and anti-epileptic drug development
Katherine M.J. McMurray, Margaret G. Distler, Preetpal Sidhu, Leggy A. Arnold, Abraham A. Palmer, Leigh D. Plant*
Biochem. Soc. Trans. 2014, 42, 461-467.